Saja Baraghithy

Jerusalem, JM, Israel

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

Cannabidiol and cannabigerol ameliorate steatotic liver disease via phosphocreatine buffering and lysosomal restoration.

Cannabidiol and cannabigerol ameliorate steatotic liver disease via phosphocreatine buffering and lysosomal restoration.

Journal: British journal of pharmacology
Published: August 18, 2025

Blockade of Interleukin-6 Trans-signaling in the Presence of Certain Gut Microbiota Induces Mature-onset Obesity in Mice.

Blockade of Interleukin-6 Trans-signaling in the Presence of Certain Gut Microbiota Induces Mature-onset Obesity in Mice.

Journal: Gastro hep advances
Published: June 05, 2025

Synthesis and Pharmacological Characterization of Novel Peripheral Cannabinoid-1 Receptor Blockers Based on a Tricyclic Scaffold.

Synthesis and Pharmacological Characterization of Novel Peripheral Cannabinoid-1 Receptor Blockers Based on a Tricyclic Scaffold.

Journal: Journal of medicinal chemistry
Published: April 21, 2025

Metabolic consequences of altered kidney glucose reabsorption under normoglycemic conditions.

Metabolic consequences of altered kidney glucose reabsorption under normoglycemic conditions.

Journal: Molecular metabolism
Published: April 16, 2025

Markedly Low Prevalence of Fatty Liver Despite Obesity in Prader-Willi Syndrome: A Search for Protective Genetic Markers.

Markedly Low Prevalence of Fatty Liver Despite Obesity in Prader-Willi Syndrome: A Search for Protective Genetic Markers.

Journal: Journal of clinical and experimental hepatology
Published: January 30, 2025

CD59 drives diet-induced obesity and glucose intolerance, insulin resistance, and metabolic dysfunction-associated steatotic liver disease.

CD59 drives diet-induced obesity and glucose intolerance, insulin resistance, and metabolic dysfunction-associated steatotic liver disease.

Journal: npj metabolic health and disease
Published: October 19, 2024

Characterization of Neurensin-2 knockout mice: insights into stress-resilience mechanisms.

Characterization of Neurensin-2 knockout mice: insights into stress-resilience mechanisms.

Journal: Translational psychiatry
Published: September 02, 2024

5-Methoxy-2-aminoindane Reverses Diet-Induced Obesity and Improves Metabolic Parameters in Mice: A Potential New Class of Antiobesity Therapeutics.

5-Methoxy-2-aminoindane Reverses Diet-Induced Obesity and Improves Metabolic Parameters in Mice: A Potential New Class of Antiobesity Therapeutics.

Journal: ACS pharmacology & translational science
Published: June 09, 2024

The Autophagic Activator GHF-201 Can Alleviate Pathology in a Mouse Model and in Patient Fibroblasts of Type III Glycogenosis.

The Autophagic Activator GHF-201 Can Alleviate Pathology in a Mouse Model and in Patient Fibroblasts of Type III Glycogenosis.

Journal: Biomolecules
Published: June 05, 2024

Renal Mitochondrial ATP Transporter Ablation Ameliorates Obesity-Induced CKD.

Renal Mitochondrial ATP Transporter Ablation Ameliorates Obesity-Induced CKD.

Journal: Journal of the American Society of Nephrology : JASN
Published: May 22, 2023

Characterization of metabolic alterations in the lean metabolically unhealthy alpha defensin transgenic mice.

Characterization of metabolic alterations in the lean metabolically unhealthy alpha defensin transgenic mice.

Journal: iScience
Published: May 19, 2023

Hepatic targeting of the centrally active cannabinoid 1 receptor (CB1R) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes.

Hepatic targeting of the centrally active cannabinoid 1 receptor (CB1R) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes.

Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: July 12, 2022
Showing 1-12 of 24

Last Updated: 09/26/2026